Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to Pfizer Inc’s (NYSE:PFE) Xtandi (enzalutamide).
The data showed that Erleada (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC).
Presented at the 6th European Congress of Oncology Pharmacy, the study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC.
The analysis demonstrated patients with mCSPC who initiated Erleada as their first ARPI had a statistically significant 23% reduction in their risk of death at 24 months compared to patients who initiated enzalutamide.
Also Read: Humana Faces Sharp Decline In Medicare Star Ratings For 2025, Braces For 2026 Revenue Hit
The proportion of patients alive at 24 months (87.6%) observed in the Erleada cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4%).
TITAN demonstrated a statistically significant superior overall survival benefit of Erleada plus androgen deprivation therapy (ADT) compared to ADT alone at the primary analysis after a median of 22.7 months of follow-up and at the final analysis after a median of 44 months of follow-up.
On Tuesday, Johnson & Johnson announced an investment of more than $2 billion to build a biologics manufacturing facility in Wilson, North Carolina.
The new facility will expand the production of the company’s portfolio and pipeline of biologics in support of its broader plan to advance more than 70 novel therapies and product expansion filings and launches by the end of the decade.
When fully operational, the site will employ approximately 420 full-time employees.
Construction is anticipated to begin in the first half of 2025.
Price Action: JNJ stock is down 0.26% at $161.58 at last check Wednesday.
Photo via Shutterstock
Read Next:
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.